Doug Williams’ Codiak Biosciences gets $61M Series B for exosome work
This closes out Codiak Biosciences' Series B round first announced alongside its November launch - bringing the fledgling startup's funding to $92 million.
This closes out Codiak Biosciences' Series B round first announced alongside its November launch - bringing the fledgling startup's funding to $92 million.
Former Biogen R&D chief Doug Williams is launching a biotech startup called Codiak BioSciences with $80 million. It is developing exosomes as a new diagnostic and therapeutic tool, beginning with pancreatic cancer.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.